Gilead Sciences: Long-acting HIV-1 shell inhibitor Lenacapavir (GS-6207) clinically performs well
-
Last Update: 2020-07-14
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Gilead Sciences today released the latest data from an ongoing Phase 1 clinical study showing that the experimental HIV-1 shell function inhibitor Lenacapavir (GS-6207) is expected to last at least six months after a single 900 mg doseIn this study, Lenacapavir had good tolerance and no serious adverse reactions were reportedThese figures will be presented at the 23rd International AIDS ConferenceDrEric SDaar, a professor of medicine at the David Geffen School of Medicine at UCLA, said: "Long-acting antiretroviral therapy can help address patient compliance and provide more treatment options for people living with HIVLenacapavir's safety and pharmacokinetic characteristics support a long-acting regimen that is administered every 6 months."Lenacapavir is a research drug that is being used in combination with other antiretroviral drugs as part of a long-acting treatment programmeLenacapavir destroys the HIV shell at several stages of the virus's life cycle, which is a multi-polymer that is necessary for virus replicationIn May 2019, theFDAawarded Lenacapavir breakthrough therapy for treatment of multidrug-resistant AIDS patients
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
